WO2010147677A3 - Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone - Google Patents

Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone Download PDF

Info

Publication number
WO2010147677A3
WO2010147677A3 PCT/US2010/001785 US2010001785W WO2010147677A3 WO 2010147677 A3 WO2010147677 A3 WO 2010147677A3 US 2010001785 W US2010001785 W US 2010001785W WO 2010147677 A3 WO2010147677 A3 WO 2010147677A3
Authority
WO
WIPO (PCT)
Prior art keywords
ozone
ischemic brain
acute ischemic
treatment
brain stroke
Prior art date
Application number
PCT/US2010/001785
Other languages
French (fr)
Other versions
WO2010147677A2 (en
Inventor
Joseph S. Latino
Steven A. Keyser
Original Assignee
Acquisci, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acquisci, Inc. filed Critical Acquisci, Inc.
Priority to CA2765479A priority Critical patent/CA2765479A1/en
Priority to CN2010800343177A priority patent/CN102802643A/en
Priority to IN534DEN2012 priority patent/IN2012DN00534A/en
Priority to EP10789881A priority patent/EP2442819A4/en
Priority to AU2010260467A priority patent/AU2010260467A1/en
Priority claimed from US12/819,886 external-priority patent/US20100316727A1/en
Priority claimed from US12/819,875 external-priority patent/US20100316730A1/en
Priority claimed from US12/819,871 external-priority patent/US20100318014A1/en
Publication of WO2010147677A2 publication Critical patent/WO2010147677A2/en
Publication of WO2010147677A3 publication Critical patent/WO2010147677A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods of treating mammalian subjects suffering from, or believed to be suffering from, acute ischemic brain stroke, cardiovascular disease, inflammatory disease or any of the conditions or symptoms related to those diseases, are disclosed in which a biological fluid withdrawn from the subject is processed through an ozone delivery system to deliver a measured amount of ozone to the biological fluid to produce a treated fluid that has a quantifiable absorbed-dose of ozone which, upon re- introduction of the treated fluid containing the quantifiable absorbed-dose of ozone to the subject, effectively treats any number of described disease conditions and symptoms. Methods for manufacturing medicaments for treatment of acute ischemic brain stroke, cardiovascular disease, inflammatory disease or any of the conditions or symptoms related to those diseases, are also disclosed.
PCT/US2010/001785 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone WO2010147677A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2765479A CA2765479A1 (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
CN2010800343177A CN102802643A (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
IN534DEN2012 IN2012DN00534A (en) 2009-06-19 2010-06-21
EP10789881A EP2442819A4 (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
AU2010260467A AU2010260467A1 (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US26909109P 2009-06-19 2009-06-19
US26908709P 2009-06-19 2009-06-19
US26909009P 2009-06-19 2009-06-19
US61/269,087 2009-06-19
US61/269,091 2009-06-19
US61/269,090 2009-06-19
US12/819,886 US20100316727A1 (en) 2003-07-31 2010-06-21 Treatment of inflammatory disorders with ozone
US12/819,875 US20100316730A1 (en) 2003-07-31 2010-06-21 Treatment of cardiovascular diseases with ozone
US12/819,875 2010-06-21
US12/819,871 2010-06-21
US12/819,886 2010-06-21
US12/819,871 US20100318014A1 (en) 2003-07-31 2010-06-21 Treatment of acute ischemic brain stroke with ozone

Publications (2)

Publication Number Publication Date
WO2010147677A2 WO2010147677A2 (en) 2010-12-23
WO2010147677A3 true WO2010147677A3 (en) 2011-05-12

Family

ID=43356980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/001785 WO2010147677A2 (en) 2009-06-19 2010-06-21 Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone

Country Status (5)

Country Link
EP (1) EP2442819A4 (en)
AU (1) AU2010260467A1 (en)
CA (1) CA2765479A1 (en)
IN (1) IN2012DN00534A (en)
WO (1) WO2010147677A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500277A4 (en) 2016-08-19 2020-04-15 Immunores-Therapeutics, LLC Gas treatment delivery systems and methods
WO2018035504A1 (en) 2016-08-19 2018-02-22 Lane Ronald Howard Gas treatment delivery systems and methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005348774A (en) * 2004-06-08 2005-12-22 Masako Negishi Treatment method for disease of animal and treatment apparatus for the same
US20060210644A1 (en) * 2004-12-16 2006-09-21 Bruce Levin Materials, methods, and devices for treatment of arthropathies and spondylopathies
US20060217359A1 (en) * 2003-09-05 2006-09-28 Paul Wentworth Therapeutic procedures
EP1932524A1 (en) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmaceutical preparations for treating inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
CA2308105A1 (en) * 2000-05-11 2001-11-11 Vasogen Ireland Limited Treatment of il-10 deficiencies
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
US7736494B2 (en) * 2003-07-31 2010-06-15 Acquisci, Inc. Ozone delivery system including a variable pitch gas-fluid contact device
WO2006007710A2 (en) * 2004-07-20 2006-01-26 Vasogen Ireland Limited Acute inflammatory condition treatment
WO2007115398A1 (en) * 2006-04-10 2007-10-18 Vasogen Ireland Limited Treatment of elevated c-reactive protein levels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217359A1 (en) * 2003-09-05 2006-09-28 Paul Wentworth Therapeutic procedures
JP2005348774A (en) * 2004-06-08 2005-12-22 Masako Negishi Treatment method for disease of animal and treatment apparatus for the same
US20060210644A1 (en) * 2004-12-16 2006-09-21 Bruce Levin Materials, methods, and devices for treatment of arthropathies and spondylopathies
EP1932524A1 (en) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Pharmaceutical preparations for treating inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2442819A4 *

Also Published As

Publication number Publication date
WO2010147677A2 (en) 2010-12-23
AU2010260467A1 (en) 2012-02-09
EP2442819A2 (en) 2012-04-25
IN2012DN00534A (en) 2015-06-05
CA2765479A1 (en) 2010-12-23
EP2442819A4 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
WO2012083132A3 (en) Diagnosis and treatments relating to th2 inhibition
MX2019002669A (en) Methods of treating behavioral symptoms of neurological and mental disorders.
WO2011057003A3 (en) Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
IL222252A0 (en) Methods, system and apparatus for the detection, diagnosis and treatment of biological rhythm disorders
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
WO2015118537A3 (en) Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
MX2019005130A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
PL2318035T3 (en) Methods and compositions for the treatment of symptoms of neurological and mental health disorders
WO2009100131A3 (en) Process to diagnose or treat brain injury
EP2268140A4 (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders
IL216967A0 (en) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases
WO2011156248A3 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
HK1171370A1 (en) A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
WO2008147483A8 (en) Neurogenic compounds
HK1152649A1 (en) Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
WO2008053484A3 (en) Preparation of heavy metal-containing nano-liposomes and their uses in medical therapy
WO2010147677A3 (en) Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
NZ597115A (en) Method of treating age related disorders with fujimycin
MX2022010890A (en) Treatment and diagnosis of inflammatory disorders.
Khemthong et al. Effect of musical training on reaction time: A randomized control trial in Thai elderly individuals.
PT2470213E (en) Composition for treatment of neurodegenerative diseases or disorders, method and use comprising electromagnetically irradiated yeast
WO2009061847A3 (en) Methods for diagnosing and treating pelvic pain disorders via beta-catenin
Wu et al. The assessment of anxiety and depression state in Meniere's disease patients
ATE498391T1 (en) LIQUID COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF VARIOUS METABOLIC BONE DISEASES, USE THEREOF AND PREPARATION PROCESS.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080034317.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10789881

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2765479

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010260467

Country of ref document: AU

Ref document number: 534/DELNP/2012

Country of ref document: IN

Ref document number: 2010789881

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010260467

Country of ref document: AU

Date of ref document: 20100621

Kind code of ref document: A